PITTSBURGH, April 25, 2024 /PRNewswire/ -- PANTHERx®?Rare, the leader in rare disease pharmacy, patient access, and support services in?the United States, is pleased to announce three new expansions that will facilitate the company's continued growth and enhance its innovative capabilities to serve more people living with rare and devastating conditions.
PITTSBURGH, April 25, 2024 /PRNewswire/ -- An exciting advancement for the specialty pharmacy industry, KEEP announced a strategic partnership with PANTHERx Rare, a leader in rare disease product patient access and support services in the US. This collaboration is set to enhance the home-based therapy experience for patients living with rare and orphan conditions.
PITTSBURGH, Feb. 5, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Chiesi Global Rare Diseases, a business unit of the Chiesi Group, for the distribution of Filsuvez® topical gel, the first approved treatment for wounds associated with both dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.1
PITTSBURGH, Jan. 8, 2024 /PRNewswire/ -- PANTHERx Rare, one of the nation's leading rare pharmacies, today announced the appointment of Bansi Nagji to the new board position of Executive Chair as part of the Company's ongoing strategic development and growth.
PITTSBURGH, Aug. 2, 2023 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it has been selected by UCB as a limited distribution partner to provide RYSTIGGO® (rozanolixizumab-noli), the first and only FDA-approved targeted treatment for both anti- acetylcholine receptor (AChR) anti- muscle-specific tyrosine kinase (MuSK) antibody positive adult patients with generalized myasthenia gravis (gMG).1 For more information, please see the Full Prescribing Information for RYSTIGGO®.
Wilson Disease is a rare genetic disorder which is caused by a mutation in the ATP7B gene. This results in the accumulation of copper throughout the body, which can lead to a wide range of symptoms such as tremours, anxiety, jaundice due to liver injury and Kayser-Fleischer rings (brown rings in the corneas of the eyes). Serious complications include: problems with the liver and kidneys; neurological issues that affect gait and speech; mental health problems like depression and psychosis; and blood disorders such as jaundice and anaemia.
PITTSBURGH, April 19, 2023 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
PANTHERx Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol)....
PANTHERx® Rare Pharmacy Selected by ChemoCentryx to Distribute TAVNEOS™ (avacopan) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole). The drug, an oral film formulation of riluzole, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS).